Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2015

View Archived Issues

High-fat meal alters the pharmacokinetic profile of atorvastatin/metformin FDC

Galapagos introduces a new branimycin derivative DNA polymerase III inhibitor

Prolastin-C designated an orphan drug in U.S. for treating type 1 diabetes

Ruthigen and Pulmatrix to merge

GSK plans first-in-human study of GSK-2330811 for inflammatory and fibrotic diseases

Lakewood-Amedex and University of Jyvaskyla to test bisphosphocins for Borrelia burgdorferi

Galapagos regains rights to GLPG-1690 and announces end of alliance with Janssen

ADRA2A polymorphism associated with breast cancer severity

New genetic biomarkers associated with Hirschprung disease

Egalet earns milestone payment triggered by advancement of Shionogi's S-718632

Qiagen acquires CTC technology, enters companion diagnostic agreement with Tokai

Symbiomix's antibacterial drug candidate is safe and well tolerated

Actavis completes acquisition of Allergan

GlaxoSmithKline initiates phase III program of retosiban in preterm labor

Fujifilm reports novel ATM kinase inhibitors

Roche presents novel PAMs of muscarinic M1 receptor

Senju Pharmaceutical presents miRNA-203 inhibitor

GliaCure receives grant for phase Ib Alzheimer's trial

Neurotrope reports final results from phase IIa safety study of bryostatin 1 for Alzheimer's

Merck & Co. patents adenosine A2A receptor antagonists

Nektar Therapeutics discloses top-line results from phase III trial of NKTR-102 in breast cancer

Phase III study of Imbruvica combination meets primary endpoint

Celldex Therapeutics and Roche to evaluate the combination of varlilumab and MPDL-3280A

Iclusig now has U.S. and E.U. orphan drug status for gastrointestinal stromal tumors

Lundbeck initiates phase III study of clobazam in children with Dravet syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...